ZYME
NASD Zymeworks Inc.$25.36 ↑ +0.10 (+0.40%) Trading Up from the previous close of $25.26
- YTD change
- -3.68%
- vs 20-day SMA
- -4.34%
- vs 200-day SMA
- +1.06%
Price ranges
Price & Performance
-2.09 (-7.64%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 57.0% away from all-time highs of $59.03
- ZYME is down 4% since the beginning of the year
- ZYME is up 50% over the past 12 months
- ZYME is down 4% over the past 1 month
- 7% of all ZYME investors are betting against ZYME
ZYME reads not so good: price sits above one of the two key moving averages, the 12-month move is +49.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.10
- Last 5 days
- -2.31%
- vs 8-day SMA
- -2.67%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
